Geron Presents Positive RYTELO Data for LR-MDS at ASCO & EHA, Highlights Efficacy, Myelofibrosis Program Progress

Geron Corporation (NASDAQ:GERN) is one of the best low priced pharma stocks to buy now. Earlier on May 28, Geron Corporation presented new data on RYTELO (imetelstat) at the 2025 American Society of Clinical Oncology/ASCO Annual Meeting and the European Hematology Association/EHA 2025 Congress. These presentations underscored the efficacy and safety of RYTELO across patients with lower-risk myelodysplastic syndromes/LR-MDS with transfusion-dependent anemia and provided updates on its myelofibrosis/MF program.

RYTELO is a first-in-class oligonucleotide telomerase inhibitor that is approved in the US for adult patients with low-to-intermediate-1 risk LR-MDS with transfusion-dependent anemia requiring 4 or more red blood cell units over 8 weeks, who have not responded to, lost response to, or are ineligible for erythropoiesis-stimulating agents (ESAs). It is administered as a 2-hour intravenous infusion every 4 weeks.

A close-up of a laboratory technician in a laboratory, measuring a newly developed biopharmaceutical drug.

RYTELO also received marketing authorization in the European Union on March 11 this year as a monotherapy for adults with transfusion-dependent anemia due to very low, low, or intermediate-risk LR-MDS without an isolated deletion 5q cytogenetic (non-del 5q) abnormality, who had an unsatisfactory response to or are ineligible for erythropoietin-based therapy. The drug works by inhibiting telomerase enzymatic activity, which is often increased in malignant bone marrow cells, leading to telomere shortening and induction of malignant cell death.

Geron Corporation (NASDAQ:GERN) is a commercial-stage biopharmaceutical company that develops therapeutic products for oncology.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.